NCT04479306 2026-04-16
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
5 trialsNCT06525246 2026-03-13
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT02917993 2026-02-09
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 1/2 Completed
NCT03133546 2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed